Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 354

1.

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; US01 Study Team.

Arch Neurol. 2004 Oct;61(10):1563-8.

PMID:
15477510
[PubMed - indexed for MEDLINE]
2.

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.

Rinne UK, Larsen JP, Siden A, Worm-Petersen J.

Neurology. 1998 Nov;51(5):1309-14.

PMID:
9818851
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group.

Acta Neurol Scand. 2002 Apr;105(4):245-55.

PMID:
11939936
[PubMed - indexed for MEDLINE]
4.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
[PubMed - indexed for MEDLINE]
5.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
[PubMed - indexed for MEDLINE]
6.

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.

Mov Disord. 1997 Jul;12(4):497-505.

PMID:
9251066
[PubMed - indexed for MEDLINE]
7.

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group.

Lancet. 2005 Mar 12-18;365(9463):947-54.

PMID:
15766996
[PubMed - indexed for MEDLINE]
8.

Entacapone in the treatment of Parkinson's disease.

Schrag A.

Lancet Neurol. 2005 Jun;4(6):366-70. Review.

PMID:
15907741
[PubMed - indexed for MEDLINE]
9.

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

Brooks DJ, Sagar H; UK-Irish Entacapone Study Group.

J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9.

PMID:
12876237
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.

Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I; F-01 Study Group.

Eur Neurol. 2001;45(2):111-8.

PMID:
11244274
[PubMed - indexed for MEDLINE]
11.
12.
13.

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A.

J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94.

PMID:
10766888
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.

Ferreira JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L, Soares-da-Silva P; BIA-3202-202 Study Investigators.

CNS Neurosci Ther. 2010 Dec;16(6):337-47. doi: 10.1111/j.1755-5949.2010.00145.x.

PMID:
20653695
[PubMed - indexed for MEDLINE]
15.

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A.

J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):186-9.

PMID:
8126502
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The role of COMT inhibition in the treatment of Parkinson's disease.

Poewe W.

Neurology. 2004 Jan 13;62(1 Suppl 1):S31-8. Review.

PMID:
14718678
[PubMed - indexed for MEDLINE]
17.

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K; ComQol Study Group.

Acta Neurol Scand. 2005 Jan;111(1):21-8.

PMID:
15595934
[PubMed - indexed for MEDLINE]
18.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Erratum in: Ann Neurol. 2010 Sep;68(3):412-3.

PMID:
20582993
[PubMed - indexed for MEDLINE]
19.

[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].

Kulisevsky J.

Neurologia. 1999 Aug-Sep;14(7):349-58. Review. Spanish.

PMID:
10570622
[PubMed - indexed for MEDLINE]
20.

Bimodal administration of entacapone in Parkinson's disease patients improves motor control.

Bet L, Bareggi SR, Pacei F, Bondiolotti G, Meola G, Schapira AH.

Eur J Neurol. 2008 Mar;15(3):268-73. doi: 10.1111/j.1468-1331.2007.02043.x.

PMID:
18290846
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk